Albert Bourla (Greek: Άλμπερτ Μπουρλά; born October 21, 1961) is a Greek-American veterinarian and businessman known for serving as the chairman and chief executive officer of the pharmaceutical company Pfizer. He joined the company in 1993 and has held several executive roles across Pfizer's divisions.

As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose, “Breakthroughs that change patients’ lives,” with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

6 days ago · Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after Kennedy was confirmed. ... Pfizer CEO Albert Bourla had dinner with RFK Jr ...

6 days ago · Pfizer CEO Albert Bourla addresses the audience as part of a session on AI during the World Economic Forum (WEF) annual meeting in Davos on January 23, 2025.

Jan 16, 2025 · Take a look below to see where Pfizer, and our CEO Albert Bourla, landed on a variety of lists—including TIME’s 100 Most Influential Companies and Forbes America’s Dream Employers—recognizing both our work in the lab and in the office. …

“2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and financial commitments, strengthened our company and, most importantly, reached millions of patients with our medicines and vaccines,” said Dr. Albert Bourla, Chairman and Chief Executive Officer.

6 days ago · Albert Bourla, CEO of Pfizer, Bourla warned that if ‘the megaphone’ of the US health department started sowing doubt about vaccines ‘we may lose another 5% of vaccination ...

Mar 16, 2023 · Albert Bourla says he never planned to become a CEO. When he joined Pfizer in 1993, after earning a Ph.D. from a veterinary school in Greece, Bourla says he knew his calling was industry, not academia. He said clarity about his true passion has been one of the foundations of his success.

Nov 9, 2021 · Just over a year after assuming the role of chief executive, Bourla found himself facing the unthinkable – a once-in-a-lifetime global pandemic. Bourla and Pfizer reacted quickly to the threat of COVID-19, investing more than $2 billion dollars at-risk in pursuit of a safe and effective vaccine.